{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-010231","form_type":"8-K","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2022-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.421471+00:00","generated_at":"2026-06-26T22:47:59.973718+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cogent Biosciences Q4/FY2021 net loss $24.9M/$72.3M; three bezuclastinib trials enrolling","bullets":["Cash $219.7M at Dec 31, 2021, sufficient to fund operations into 2024.","APEX Phase 2 trial in AdvSM on track for initial data in H1 2022; SUMMIT (NonAdvSM) and PEAK (GIST) actively enrolling.","Raised ~$38M via ATM in Q4 2021; shares sold at $9.25-$10.30.","R&D expenses $55.9M in FY2021 vs $25.7M in FY2020, driven by trial start-up costs and research team expansion.","Appointed Dr. Zamaneh Mikhak as SVP Head of Clinical Development; R&D Investor Event on April 8, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-010231","json":"https://secwatch.observer/filing/0001564590-22-010231.json","markdown":"https://secwatch.observer/filing/0001564590-22-010231.md","text":"https://secwatch.observer/filing/0001564590-22-010231.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000156459022010231/0001564590-22-010231-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000156459022010231/cogt-8k_20220315.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T22:47:59.973718+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}